The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Researchers at ASH shared Phase III data comparing the pre- and five-year posttreatment adjusted annualized bleeding rates, ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.